NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, today released findings from its 2024 LGBTQ+ family building survey. The report, which surveyed over 1,100 LGBTQ+ individuals in the U.S. planning to build their families, highlights the unique challenges LGBTQ+ patients face, including struggles with insufficient access to care, financial constraints, and lack of mental health support throughout their family building journey.
Progyny’s survey underscores the pivotal role employers can play in providing inclusive and comprehensive family building benefits that support all paths to parenthood. The findings highlight that employers can significantly improve the lives of LGBTQ+ employees by providing extensive support and resources for family building – these benefits are proven to promote a more inclusive workplace and strengthen employee loyalty. This data equips benefit decision makers with the insights needed to effectively support LGBTQ+ employees throughout their fertility and family building journeys.
"At Progyny, we believe that everyone deserves the opportunity to build their family, regardless of their background or identity," said Pete Anevski, CEO of Progyny. "For the LGBTQ+ community, this often means navigating additional hurdles and challenges. By adopting comprehensive and inclusive family building benefits, employers can help ensure that every individual has access to the care and resources they need to realize their dream of becoming a parent."
Key findings
Of the LGBTQ+ individuals surveyed:
"Inclusive family building benefits are transformative for employees on their journey to parenthood, especially those in the LGBTQ+ community," said Cynthia McEwen, Head of DE&I at Progyny. "These benefits not only provide crucial support and resources but also send a powerful message of acceptance and validation. When employers offer comprehensive family building benefits, they foster a sense of belonging, company allegiance, and demonstrate their understanding of the importance of equity, inclusion, and access.”
Progyny partners with over 460 leading employers to deliver personalized and impactful fertility and family building benefits. Progyny’s equitable benefit design ensures access to enrollees of all genders, sexual orientations, and relationship statuses, and provides access to comprehensive coverage for services including preconception, IUI, IVF, fertility preservation, postpartum, adoption, and surrogacy. Each patient also has convenient access to over 1,000 of the nation’s most sought-after fertility specialists so they can choose a physician who best meets their needs, as well as concierge support from a dedicated fertility coach to ease the stress and anxiety common to fertility treatment and family building journeys.
For more information about Progyny’s LGBTQ+ Family Building Survey, visit progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a transformative fertility, family building and women’s health benefits solution, trusted by the nation’s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.
For Further Information, Please Contact:
Investors:
James Hart
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Alexis Ford
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$16.90 |
Daily Change: | 2.19 14.89 |
Daily Volume: | 3,684,535 |
Market Cap: | US$1.440B |
November 14, 2024 November 12, 2024 August 06, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB